Attached files
file | filename |
---|---|
EX-10.1 - DONOHOE AGREEMENT DATED AS OF MAY 19, 2021. - Ainos, Inc. | amar_ex101.htm |
8-K - FORM 8-K - Ainos, Inc. | amar_8k.htm |
Exhibit
99.1
Ainos Announces FINRA Approval of
Name Change and Ticker Symbol Change to “AIMD”, Engages
Firm to Explore Listing Requirements of National Securities
Exchanges
San
Diego, CA, May 24, 2021 – Ainos, Inc., f/k/a Amarillo Biosciences, Inc.
(“we”, “our”, or the
“Company”), (OTCPK: AIMD), is pleased to announce that
the Financial Industry Regulatory Authority, Inc.
(“FINRA”) approved the Company’s name change to
“Ainos, Inc.” and “AIMD” as its new ticker
symbol.
Effective
today, the Company's common stock will trade under the symbol
"AIMD” and the new CUSIP number identifying our common stock
is 00902F105. These changes follow the Company’s
announcement in April 21, 2021 of the successful completion of a
securities purchase transaction with Ainos, Inc., a Cayman Islands
corporation (the “Investor” or “Ainos
KY”).
The
Company has also signed a consulting agreement with Donohoe
Advisory Associates LLC to assist the Company in evaluating listing
requirements of National Securities Exchanges in the
U.S.
About Ainos, Inc.
Ainos,
Inc., a Texas corporation (f/k/a Amarillo Biosciences, Inc.) is a
diversified healthcare company engaged in the discovery and
development of pharmaceutical and biotech products. Our goal
is to introduce novel products that actively stimulate and
rejuvenate the human body to combat disease and enhance the ability
to heal. The Company is currently focusing on point-of-care
testing rapid test kit products that include diagnostics for
COVID-19 (SARS CoV2 Antigen Rapid Test), pneumonia, vaginitis and
helicobacter pylori (H. pylori) bacterial infection. The Company
currently has offices in the United States and Taiwan.
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
This
press release contains “forward-looking statements”
within the meaning of the safe harbor provisions of the U.S.
Private Securities Litigation Reform Act of 1995. Forward-looking
statements can be identified by words such as
“anticipate,” “believe,”
“estimate,” “expect,” “intend,”
“plan,” “predict,” “project,”
“target,” “future,” “seek,”
“likely,” “strategy,” “may,”
“should,” “will,” and similar references to
future periods. Forward-looking statements are neither historical
facts nor assurances of future performance. Instead, they are based
only on our current beliefs, expectations, and assumptions
regarding the future of our business, future plans and strategies,
projections, anticipated events and trends, the economy, and other
future conditions. Because forward-looking statements relate to the
future, they are subject to inherent uncertainties, risks, and
changes in circumstances that are difficult to predict and many of
which are outside of our control. Our actual results may differ
materially from those indicated in the forward-looking statements.
Therefore, you should not rely on any of these forward-looking
statements.
Important
factors that could cause our actual results to differ materially
from those indicated in the forward-looking statements include,
among others, the following: the Company’s ability to meet
listing requirements of National Securities Exchanges; the
Company’s limited cash and history of losses; the
Company’s ability to achieve profitability; intense
competition and rapidly advancing technology in the Company’s
industry that may outpace its technology; customer demand for the
products and services the Company develops; the impact of
competitive or alternative products, technologies and pricing; the
Company’s ability to manufacture any products it develops;
the Company’s ability to license and commercialize its patent
assets; general economic conditions and events and the impact they
may have on the Company and its potential customers, including but
not limited to the impact of COVID-19; the Company’s ability
to obtain adequate financing in the future; the impact of
promulgation and implementation of regulations by the U.S. Food and
Drug Administration (“FDA”) and by foreign governmental
authorities with functions similar to those of the FDA on the
Company’s operations and technology; lawsuits and other
claims by third parties or investigations by various regulatory
agencies governing the Company’s operations; the
Company’s ability to secure regulatory approvals for its
products; and our success in managing the risks involved in the
foregoing items.
Any
forward-looking statement made by us in this press release speaks
only as of the date on which such statement is made. New factors
emerge from time to time and it is not possible for management to
predict all such factors, nor can it assess the impact of any such
factor on the business or the extent to which any factor, or
combination of factors, may cause results to differ materially from
those contained in any forward-looking statement. Readers should
also review the risks and uncertainties listed in our most recent
Annual Report on Form 10-K and other reports we file with the U.S.
Securities and Exchange Commission. We undertake no obligation to
publicly update any forward-looking statement, whether written or
oral, that may be made from time to time, whether as a result of
new information, future developments or otherwise.
Contact:
AINOS,
INC. (f/k/a Amarillo Biosciences, Inc.)
Lawrence
Lin
Tel:
(806) 376-1741
Email:
lawrence@ainos.com